Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (174,523)	$ (60,011)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	492	9
Change in fair value of preferred stock tranche liability		17,030
Research and development license expense	9,750	9,000
Stock-based compensation	18,184	3,354
Other	388
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(3,361)	(6,585)
Accounts payable	14,494	1,961
Accrued expenses and other liabilities	17,542	4,512
Due to related party	(8)	1
Net cash used in operating activities	(117,042)	(30,729)
Cash flows from investing activities
Purchase of research and development license	(6,250)	(9,000)
Purchase of property, plant and equipment	(15,304)	(82)
Net cash used in investing activities	(21,554)	(9,082)
Cash flows from financing activities
Proceeds from Term Loan, net	39,957
Proceeds from initial public offering, net of underwriting discounts and commission and other offering costs		165,854
Payment of shelf registration costs	(360)
Other	(514)
Proceeds from note payable to related party		1,673
Repayment of note payable to related party		(1,673)
Net cash provided by financing activities	39,083	291,064
Net (decrease) increase in cash, cash equivalents and restricted cash	(99,513)	251,253
Cash, cash equivalents and restricted cash at the beginning of the period	251,253
Cash, cash equivalents and restricted cash at the end of the period	151,740	251,253
Cash and cash equivalents	149,103	251,253
Restricted cash	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest	641	28
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	8,282	214
Acquisition of property, plant and equipment funded by landlord	606
Build-to-suit lease liability	26,250
Deferred offering costs not yet paid	141
Reclassification of preferred stock tranche liability		18,080
Allocation of preferred stock tranche liability		1,050
Conversion of Series A and Series B convertible preferred stock to common stock		142,240
Purchase of research and development license not yet paid	$ 3,500
Series A Convertible Preferred Stock
Cash flows from financing activities
Proceeds from convertible preferred stock, net of issuance costs		29,395
Series B Convertible Preferred Stock
Cash flows from financing activities
Proceeds from convertible preferred stock, net of issuance costs		$ 95,815